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Table
Biomarker (ng/ml) Day 100 Grade
II-IV aGVHD
(95%CI)
p-value 6-month
TRM (95% CI)
p-value
ST2  33.9 48% (35-61) 0.045 5% (1-13) 0.001
ST2 > 33.9 64% (49-76) 23% (13-35)
TNFR1 < 4792 57% (42-69) 0.660 5% (1-13) 0.005
TNFR1 > 4792 54% (40-67) 23% (13-35)
IL8 < 51 56% (41-68) 0.652 5% (1-13) 0.005
IL8 > 51 56% (41-68) 23% (13-35)
REG3a  42 57% (42-69) 0.938 5% (1-13) 0.032
REG3a > 42 55% (40-67) 24% (13-36)
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6-month TRM, and GVHD was the most common cause of
transplant-related death. High concentrations of TNFR1, IL-8,
and REG3a were signiﬁcantly associated with 6-month TRM
and the most common cause of death in these patients was
GVHD or lung toxicity.
Conclusions: This is the ﬁrst biomarker analysis conducted
in CBT recipients. As with adult donor allografts (NEJM,
2013), high day 28 ST2 levels is associated with a subsequent
increased risk of grade II-IV and III-IV aGVHD, and 6-month
TRM. GVHD onset is after day 28 in the majority of the pa-
tients which would permit potential therapeutic interven-
tion. Thus, our ﬁndings have signiﬁcant practical
implications. Our results warrant further prospective evalu-
ation with the ultimate aim of future interventions to
ameliorate severe aGVHD and improve CBT survival.434
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Neutrophil Engraftment:
Myeloablative 93% (95%CI: 82-98)
Median 23 days (range 12-43)
Non-myeloablative 96% (95%CI: 38-99)
Median 9 days (range 7-36)
+180 Platelet Engraftment:
Myeloablative 82% (95%CI: 69-90)
Median 50 days (range 29-162)
Non-myeloablative 87% (95%CI: 62-96)
Median 34 days (range 9-59)
+100 Grade II-IV aGVHD 46% (95%CI: 35-56)
+100 Grade III-IV aGVHD 22% (95%CI: 14-31)
+180 TRM 19% (95%CI: 12-28)
1-year PFS 63% (95%CI: 51-72)Background: Calcineurin-inhibitor/MMF based prophylaxis
in DCBT is frequently associated with aGVHD. MMF dosing
in CBT has traditionally been every 12 hours (q12). We
increased MMF dosing to 1 gm every 8 hours (q8) to po-
tentially ameliorate severe aGVHD. However, the toxicity and
efﬁcacy of intensiﬁed dosing is not established.
Methods: We evaluated 173 4-6/6 HLA-matched DCBT re-
cipients (median age 39 years) transplanted for hematologic
malignancies 10/2005-5/2013. Patients received calcineurin-
inhibitor/MMF from day -3 without ATG. Before 9/2009, 83
patients (48%) received 1 gm MMF IV q12 (if 12 years 15
mg/kg/dose). From 9/2009, 90 patients (52%) received 1 gm
MMF IV q8 (15 mg/kg/dose if >12 years and <50 kg, or 20
mg/kg/dose if 12 years).
Results: The median infused CD34+ cell doses of the domi-
nant CB unit were similar in the groups. There were no dif-
ferences in the speed or success of engraftment, day 180
TRM, or 1-year PFS (Table). Day 100 grade II-IV aGVHD were
similar in the groups (46% vs 53%), and decreased day 100
grade III-IV aGVHD in the q8 group was suggested. As all
patients >50 kg received 1 gm/dose, we then analyzed the
effect of the total daily MMF dose/kg (regardless of dosing
interval) in all 173 patients. A total daily dose/kg above the
median was associated with a signiﬁcant reduction in severe
aGVHD [(23% (95%CI: 15-31) vs 10% (95%CI: 4-18), p¼0.033,
Figure].
Conclusions: Intensiﬁed q8 MMF dosing is safe from the
standpoint of engraftment, TRM and relapse. While the
reduction in severe aGVHD incidence in q8 MMF DCBT re-
cipients did not reach signiﬁcance, a total daily MMF dose/kg
above the median signiﬁcantly reduced severe aGVHD risk.MMF q8 Hour (n ¼ 90) P value
96% (95%CI: 87-99)
Median 24 days (range 12-40)
0.692
93% (95%CI: 17-99)
Median 12.5 days (range 8-46)
0.343
88% (95%CI: 77-94)
Median 45 days (range 29-137)
0.137
73% (95%CI: 40-90)
Median 34 days (range 26-77)
0.229
53% (95%CI: 42-63) 0.505
13% (95%CI: 7-21) 0.166
20% (95%CI: 13-29) 0.332
61% (95%CI: 50-70) 0.760
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S280Further investigation of intensiﬁed MMF dosing adjusted for
body weight with trough level monitoring for the prevention
of aGVHD in CBT recipients is strongly indicated.435
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Purpose: To determine the impact of Prosthetic Replacement
of the Ocular Surface Ecosystem (PROSE) treatment at ﬁve
years in patients with Ocular Graft versus Host Disease
(oGVHD).
Methods: All oGVHD patients seen in consultation for PROSE
treatment from 1/1/2008 e 6/30/2008 were identiﬁed
through billing records. Retrospective review of medical re-
cords, manufacturing data, and 5 year quality data was
undertaken.
Results: This 2008 oGVHD cohort was comprised of 21 pa-
tients. As of July 2013, the conclusion of the follow-up period,
6 patients were deceased and excluded from subsequent
analysis. One patient was not a candidate for PROSE treat-
ment due to not completing the training process, leaving 14
patients who were dispensed devices. After ﬁve years,
continued device wear was conﬁrmed in 10 of these 14 (71%)
patients. Discontinuation of wear was conﬁrmed in 3/14
(21%) patients. We could not ascertain wearing statusin the
remaining 1 (7%) patients. Likelihood of continued device
wear at ﬁve years is not dependent on age, sex, general
health status or proximity of residence to our clinic (p>0.05,
for each mean, by unpaired t-test). Reasons for discontinu-
ation of wear are reported. NEI VFQ-25 composite score
increased for patients wearing PROSE devices at 6 months
(D¼+26 points, p<0.001, mean¼85) with no signiﬁcant
decline after ﬁve years (D ¼-3 points, p¼0.73).
Conclusions: PROSE treatment offers continued beneﬁt, as
deﬁned by continued device wear and visual functioning at 5
years, to the majority of oGVHD candidates who were
dispensed devices. PROSE treatment is characterized by
long-term success in the management of Ocular Graft Versus
Host Disease.436
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Background: Sclerodermatous GVHD (sclerosis) is seen in
approximately 20% of patients who received initial systemic
treatment for chronic GVHD after allogeneic HCT (Inamoto et
al. Blood 2013). Published reports suggest up regulation ofPDGFR (platelet derived growth factor receptor) and TGF-b
(transforming growth factor-b) pathways in patients with
sclerosis. Both pathways are subject to inhibition by imatinib.
We probed our database to explore if TKI use post HCT, will
reduce the incidence of sclerosis in patients with CML and
Ph+ALL.
Methods: Eighty-nine consecutive patients with CML (n¼41)
or Ph+ALL (n¼48) who underwent allogeneic HCT between
2005 to 2010 were included for analysis. Average age for
transplant was 44 years (range 18-62) All patients received
GCSF-mobilized PBSC from sibling (n¼49) or unrelated do-
nors (n¼40). A majority of our patients (n¼74) received fully
myeloablative conditioning regimens (FTBI with Cytoxan or
VP-16: n¼56, TMLI based regimens n¼3, and Bu/Cy: n¼15)
while the remaining 15 patients received reduced intensity
conditioning (Flu/Mel: n¼14, Clo/Mel: n¼1). Post transplant
GVHD prophylaxis was with sirolimus/tacrolimus in 53
(60%), tacrolimus/MTX in 13 (15%), and tacrolimus/sirolimus/
MTX in 11 (12%) patients. Median follow up duration was 30
months (Range 0.03-84.8 months).
Results: 55 patients (62%) received TKI therapy post trans-
plant while 34 patients (38%) did not receive TKI due to-
cytopenias (45%), TKI intolerance or resistance (27%), GVHD
(9%), infections (6%), and/or LFT abnormalities (6%). Median
time to start TKI post-transplant was 1.9 months (range: 0.7
e 17.9 months). The median duration of TKI therapy was 9.1
months (range 0.1- 89.4 months). Thirteen of 59 surviving
patients are currently on TKI therapy at last follow up.
The cumulative incidence of grade II-IV acute GVHD in
this patient cohort was 47% (Grade III/IV: 17%). The incidence
of chronic GVHD in the entire group was 76% (limited: n¼6,
extensive: n¼62). Eight of 55 patients exposed to TKI therapy
post transplant developed sclerosis with the median onset
time of 13.8 months (range 10.3-33.1 months). Sclerosis
occurred in 5 patients during TKI therapy whereas 3 patients
developed sclerosis after discontinuation of TKI. Seven of 34
patients who did not receive TKI post-HCT developed scle-
rosis with median onset of 17.1 months (range 6.7-53.7
months). The 2-year cumulative incidence of sclerosis was
9.2% (CI: 3.9-21.2%) for the TKI exposed group and 14.8% (CI:
6.6-33.4%) in the non-TKI group (p ¼0.69).
Conclusions: To our knowledge, this is the ﬁrst cohort study
to describe the incidence of sclerosis in patients who
received TKI post-HCT. The incidence of sclerosis appeared
consistent with the reported rate in the literature. At the
power for this analysis, statistical signiﬁcance- favoring TKI
use post HCT to reduce incidence of sclerotic cGVHD, was not
achieved.437
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